These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 25786589)

  • 1. Intensity-modulated whole abdomen irradiation following adjuvant carboplatin/taxane chemotherapy for FIGO stage III ovarian cancer : four-year outcomes.
    Rochet N; Lindel K; Katayama S; Schubert K; Herfarth K; Schneeweiss A; Sohn C; Harms W; Debus J
    Strahlenther Onkol; 2015 Jul; 191(7):582-9. PubMed ID: 25786589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensity-modulated whole abdominal radiotherapy after surgery and carboplatin/taxane chemotherapy for advanced ovarian cancer: phase I study.
    Rochet N; Sterzing F; Jensen AD; Dinkel J; Herfarth KK; Schubert K; Eichbaum MH; Schneeweiss A; Sohn C; Debus J; Harms W
    Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1382-9. PubMed ID: 19628341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Helical tomotherapy as a new treatment technique for whole abdominal irradiation.
    Rochet N; Sterzing F; Jensen A; Dinkel J; Herfarth K; Schubert K; Eichbaum M; Schneeweiss A; Sohn C; Debus J; Harms W
    Strahlenther Onkol; 2008 Mar; 184(3):145-9. PubMed ID: 18330510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant Intensity Modulated Whole-Abdominal Radiation Therapy for High-Risk Patients With Ovarian Cancer (International Federation of Gynecology and Obstetrics Stage III): First Results of a Prospective Phase 2 Study.
    Arians N; Kieser M; Benner L; Rochet N; Katayama S; Sterzing F; Herfarth K; Schubert K; Schröder L; Leitzen C; Schneeweiss A; Sohn C; Debus J; Lindel K
    Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):912-920. PubMed ID: 28870790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant whole abdominal intensity modulated radiotherapy (IMRT) for high risk stage FIGO III patients with ovarian cancer (OVAR-IMRT-01) - Pilot trial of a phase I/II study: study protocol.
    Rochet N; Jensen AD; Sterzing F; Munter MW; Eichbaum MH; Schneeweiss A; Sohn C; Debus J; Harms W
    BMC Cancer; 2007 Dec; 7():227. PubMed ID: 18093313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study evaluating consolidation whole abdominal intensity-modulated radiotherapy (IMRT) in patients with advanced ovarian cancer stage FIGO III--the OVAR-IMRT-02 Study.
    Rochet N; Kieser M; Sterzing F; Krause S; Lindel K; Harms W; Eichbaum MH; Schneeweiss A; Sohn C; Debus J
    BMC Cancer; 2011 Jan; 11():41. PubMed ID: 21276234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant intensity modulated whole-abdominal radiation therapy for high-risk patients with ovarian cancer FIGO stage III: final results of a prospective phase 2 study.
    Arians N; Kieser M; Benner L; Rochet N; Schröder L; Katayama S; Herfarth K; Schubert K; Schneeweiss A; Sohn C; Lindel K; Debus J
    Radiat Oncol; 2019 Oct; 14(1):179. PubMed ID: 31639066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consolidation whole abdomen irradiation following adjuvant carboplatin-paclitaxel based chemotherapy for advanced uterine epithelial cancer: feasibility, toxicity and outcomes.
    Rochet N; Kahn RS; Niemierko A; Delaney TF; Russell AH
    Radiat Oncol; 2013 Oct; 8():236. PubMed ID: 24125168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant chemotherapy with carboplatin and taxane compared with single drug carboplatin in early stage epithelial ovarian carcinoma.
    Skírnisdóttir I; Lindborg K; Sorbe B
    Oncol Rep; 2007 Nov; 18(5):1249-56. PubMed ID: 17914581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy, early surgical reassessment, and hyperfractionated abdominal radiotherapy in stage III ovarian cancer: results of a gynecologic oncology group study.
    Randall ME; Barrett RJ; Spirtos NM; Chalas E; Homesley HD; Lentz SL; Hanna M
    Int J Radiat Oncol Biol Phys; 1996 Jan; 34(1):139-47. PubMed ID: 12118543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postoperative external beam radiation therapy and concurrent cisplatin followed by carboplatin/paclitaxel for stage III (FIGO 2009) endometrial cancer.
    Milgrom SA; Kollmeier MA; Abu-Rustum NR; Tew WP; Sonoda Y; Barakat RR; Alektiar KM
    Gynecol Oncol; 2013 Sep; 130(3):436-40. PubMed ID: 23800696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective phase I-II trial of helical tomotherapy with or without chemotherapy for postoperative cervical cancer patients.
    Schwarz JK; Wahab S; Grigsby PW
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1258-63. PubMed ID: 20932657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose whole abdominal and pelvic irradiation for treatment of ovarian carcinoma: long-term toxicity and outcomes.
    Firat S; Murray K; Erickson B
    Int J Radiat Oncol Biol Phys; 2003 Sep; 57(1):201-7. PubMed ID: 12909234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival and prognostic factors in early-stage epithelial ovarian carcinoma treated with taxane-based adjuvant chemotherapy.
    Skírnisdóttir I; Sorbe B
    Int J Gynecol Cancer; 2007; 17(6):1231-7. PubMed ID: 17425681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
    Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer.
    Kiess AP; Damast S; Makker V; Kollmeier MA; Gardner GJ; Aghajanian C; Abu-Rustum NR; Barakat RR; Alektiar KM
    Gynecol Oncol; 2012 Nov; 127(2):321-5. PubMed ID: 22850412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of relapse in stage I-II uterine papillary serous carcinoma treated with adjuvant intravaginal radiation (IVRT) with or without chemotherapy.
    Desai NB; Kiess AP; Kollmeier MA; Abu-Rustum NR; Makker V; Barakat RR; Alektiar KM
    Gynecol Oncol; 2013 Dec; 131(3):604-8. PubMed ID: 24055615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prognostic factors for survival of ovarian epithelial cancers: apropos of 287 cases].
    Brun JL; Bouzigon E; Saurel J; Chêne G; Briex M; Brun G; Hocke C
    Gynecol Obstet Fertil; 2000 Mar; 28(3):223-31. PubMed ID: 10786403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC.
    Ardizzoni A; Tiseo M; Boni L; Di Maio M; Buffoni L; Belvedere O; Grossi F; D'Alessandro V; de Marinis F; Barbera S; Caroti C; Favaretto A; Cortinovis D; Morrica B; Tixi L; Ceschia T; Parisi S; Ricardi U; Grimaldi A; Loreggian L; Navarria P; Huber RM; Belani C; Brunsvig PF; Scagliotti GV; Scolaro T
    Lung Cancer; 2016 Oct; 100():30-37. PubMed ID: 27597278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
    Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
    Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.